Casey Kraning

Apr 5, 2024 | fr.com | Andria Rae Crisler |Casey Kraning |Philip Chen |Madelyn McCormick

In this review, we discuss the most important recent developments in the biosimilars space, including new biosimilar approvals and launches, litigation under the Biologics Price Competition and Innovation Act (BPCIA), post-grant disputes on biologic drug patents before the United States Patent and Trademark Office (USPTO), and proposed legislation and regulatory activities relating to biosimilars.